Oncology and Hematology Medications

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Synopsis of Neurology, Psychiatry and Related Systemic Disorders

• Publication date

  2019-05-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1017/9781107706866.036
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Platinum-induced neurotoxicity and preventive strategies: past, present, and future.

  2015cited by this paper
• The double-edged sword: Neurotoxicity of chemotherapy.

  2015cited by this paper
• Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

  2015cited by this paper
• Nanoparticle albumin-bound paclitaxel (nab-paclitaxel): extending its indications

  2014cited by this paper
• The paradox of paclitaxel neurotoxicity: Mechanisms and unanswered questions.

  2014cited by this paper
• Chemotherapy-induced neuropathy: A comprehensive survey.

  2014cited by this paper
• Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.

  2014cited by this paper
• Neurotoxicity as a Prognostic Factor in Patients with Metastatic Breast Cancer Treated with Ixabepilone as a First-Line Therapy

  2014cited by this paper
• Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

  2013cited by this paper
• Chemotherapy‐induced peripheral neurotoxicity: A critical analysis

  2013cited by this paper
• Effects of raloxifene on cognition, mental health, sleep and sexual function in menopausal women: a systematic review of randomized controlled trials.

  2013cited by this paper
• Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials

  2012cited by this paper
• An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.

  2012cited by this paper
• Neurotoxicity Caused by the Treatment with Platinum Analogues

  2011cited by this paper
• Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient.

  2011cited by this paper
• Emerging toxic neuropathies and myopathies.

  2011cited by this paper
• Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

  2011cited by this paper
• Acute tamoxifen-induced depression and its prevention with venlafaxine.

  2009cited by this paper
• Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report.

  2009cited by this paper
• Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

  2009cited by this paper
• Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.

  2007cited by this paper
• Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma

  2007cited by this paper
• Methylene Blue for Management of Ifosfamide-Induced Encephalopathy

  2006cited by this paper
• Reversible posterior leukoencephalopathy syndrome and bevacizumab.

  2006cited by this paper
• Capecitabine-induced cerebellar toxicity.

  2006cited by this paper
• Capecitabine-induced multifocal leukoencephalopathy: A report of five cases

  2005cited by this paper
• Peripheral neuropathy associated with capecitabine

  2004cited by this paper
• Central neurotoxicity following intracarotid BCNU chemotherapy for malignant gliomas

  2004cited by this paper
• Side Effects of Ifosfamide

  2003cited by this paper
• Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy.

  2002cited by this paper
• Fluorouracil-Induced Neurotoxicity

  2000cited by this paper
• The Relationship Between Tamoxifen, Estrogen, and Depressive Symptoms

  1999cited by this paper
• An Overview of Cyclophosphamide and Ifosfamide Pharmacology

  1997cited by this paper
• High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency.

  1997cited by this paper
• High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy.

  1997cited by this paper
• Clustering of adverse drug events: analysis of risk factors for cerebellar toxicity with high-dose cytarabine.

  1992cited by this paper
• Cerebellar toxicity with high-dose cytosine arabinoside.

  1987cited by this paper
• Progressive ascending paralysis following administration of intrathecal and intravenous cytosine arabinoside. A pediatric oncology group study

  1986cited by this paper
• Encephalomyelopathy following high‐dose BCNU therapy

  1981cited by this paper

• No citing papers are available for this paper.